Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: Results of the Mabthera International Trial Group study

Annals of Oncology

Volumn 22, Issue 3, 2011, Pages 664-670

  Rieger, M ^a   Osterborg A ^b   Pettengell, R ^c   White, D ^d   Gill, D ^e   Walewski, J ^f   Kuhnt, E ^g   Loeffler, M ^g   Pfreundschuh, M ^h   Ho, A D ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d DALHOUSIE UNIVERSITY   (Canada)

^e PRINCESS ALEXANDRA HOSPITAL   (Australia)

^f INSTITUTE OF ONCOLOGY   (Poland)

^g UNIVERSITY OF LEIPZIG   (Germany)

^h SAARLAND UNIVERSITY   (Germany)

Author keywords

MInT; Primary mediastinal B cell lymphoma; Rituximab

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; LACTATE DEHYDROGENASE; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; EVENT FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; LYMPHOMA, B-CELL; MALE; MEDIASTINAL NEOPLASMS; METHOTREXATE; MIDDLE AGED; MITOXANTRONE; MULTIVARIATE ANALYSIS; PREDNISOLONE; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 79952029773     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq418     Document Type: Article

References (34)

1. Lichtenstein AK, Levine A, Taylor CR et al. Primary mediastinal lymphoma in adults. Am J Med 1980; 68: 509-514.
2. Gaulard P, Harris NL, Pileri SA et al. Primary mediastinal (thymic) large B-cell lymphoma. In Swerdlow SH, Campo E, Harris NL (eds), et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press 2008; 250-251.
3. Boleti E, Johnson PW. Primary mediastinal B-cell lymphoma. Hematol Oncol 2007; 25: 157-163.
4. Savage KJ, Monti S, Kutok JL et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871-3879.
5. Rosenwald A, Wright G, Leroy K et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851-862.
6. Todeschini G, Ambrosetti A, Meneghini V et al. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients. J Clin Oncol 1990; 8: 804-808.
7. Kirn D, Mauch P, Shaffer K et al. Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol 1993; 11: 1336-1343.
8. Hamlin PA, Portlock CS, Straus DJ et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005; 130: 691-699.
9. Haioun C, Gaulard P, Roudot-Thoraval F et al. Mediastinal diffuse large-cell lymphoma with sclerosis: a condition with a poor prognosis. Am J Clin Oncol 1989; 12: 425-429.
10. Sehn LH, Antin JH, Shulman LN et al. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 1998; 91: 717-723.
11. Todeschini G, Secchi S, Morra E et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004; 90: 372-376.
12. Zinzani PL, Martelli M, Bendandi M et al. Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica 2001; 86: 187-191.
13. Kuruvilla J, Pintilie M, Tsang R et al. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma 2008; 49: 1329-1336.
14. De Sanctis V, Finolezzi E, Osti MF et al. MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma. Int J Radiat Oncol Biol Phys 2008; 72: 1154-1160.
15. Zinzani PL, Martelli M, Magagnoli M et al. Treatment and Clinical Management of Primary Mediastinal Large B-Cell Lymphoma With Sclerosis: MACOP-B Regimen and Mediastinal Radiotherapy Monitored by 67Gallium Scan in 50 Patients. Blood 1999; 94: 3289-3293.
16. Zinzani PL, Martelli M, Bertini M et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002; 87: 1258-1264.
17. Savage KJ, Al-Rajhi N, Voss N et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006; 17: 123-130.
18. Martelli MP, Martelli M, Pescarmona E et al. MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis. Ann Oncol 1998; 9: 1027-1029.
19. Dunleavy K, Pittaluga S, Janik J et al. Primary mediastinal large B-cell lymphoma (PMBL) outcome may be significantly improved by the addition of rituximab to dose-adjusted (DA)-EPOCH and cbviates the need for radiation: results from a prospective study of 44 patients. Blood 2006; 108(11). (Abstr 209).
20. Avigdor A, Sirotkin T, Shemtov N et al. Combination of rituximab with initial chemotherapy improves outcome of primary mediastinal B-cell lymphoma: a retrospective analysis of a single institution cohort. Blood 2007; 110(11). (Abstr 1283).
21. Pfreundschuh M, Trümper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
22. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
23. Cazals-Hatem D, Lepage E, Brice P et al. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study. Am J Surg Pathol 1996; 20: 877-888.
24. Besien K van, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol 2001; 19: 1855-1864.
25. Lazzarino M, Orlandi E, Paulli M et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 1997; 15: 1646-1653.
26. Nguyen LN, Ha CS, Hess M et al. The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum. Int J Radiat Oncol Biol Phys. 2000; 47: 1281-1285.
27. Mazzarotto R, Boso C, Vianello F et al. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-2B) plus involved field radiotherapy on 53 patients. A single institution experience. Int J Radiat Oncol Biol Phys. 2007; 68: 823-829.
28. Lavabre-Bertrand T, Donadio D, Fegueux N et al. A study of 15 cases of primary mediastinal lymphoma of B-cell type. Cancer 1992; 69: 2561-2566.
29. Perrone T, Frizzera G, Rosai J. Mediastinal diffuse large-cell lymphoma with sclerosis. A clinicopathologic study of 60 cases. Am J Surg Pathol 1986; 10: 176-191.
30. Massoud M, Koscielny S, Lapusan S et al. Primary mediastinal large B-cell lymphomas treated with dose-intensified CHOP alone or CHOP combined with radiotherapy. Leuk Lymphoma 2008; 49: 1510-1515.
31. Kolonic SO, Dzebro S, Kusec R et al. Primary mediastinal large B-cell lymphoma: a single-center study of clinicopathologic characteristics. Int J Hematol 2006; 83: 331-336.
32. Vassilakopoulos TP, Angelopoulou MK, Galani Z et al. Rituximab-CHOP (R-CHOP) and radiotherapy (RT) for primary mediastinal large B-cell lymphoma (PMLBCL). Blood 2006; 108(11). (Abstr 2745).
33. Pfreundschuh M, Trümper L, Osterborg A et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008; 9: 435-444.
34. Zinzani PL, Stefoni V, Finolezzi E et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large Bcell lymphoma: a retrospective study. Clin Lymphoma Myeloma 2009; 9: 381-385.